Altos Labs and the quest for immortality: but can we live longer right now?

Mikhail V. Blagosklonny

1Roswell Park Cancer Institute, Buffalo, NY 14263, USA

Correspondence to: Mikhail V. Blagosklonny, email: Blagosklonny@oncotarget.com, Blagosklonny@rapalogs.com

Keywords: aging; longevity; lifespan; geroscience; rapalogs; gerostatics

Received: April 04, 2022 Accepted: April 16, 2022 Published: April 22, 2022

Copyright: © 2022 Blagosklonny. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Some visionaries prefer to dream of immortality rather than to actually live longer. Here I discuss how combining rapamycin with other modalities may let us live long enough to benefit from future discoveries in cellular reprogramming and what needs to be done at Altos Labs to make this happen.

People do not actually need to live longer to be happy; they just need to believe that they will live longer to be happy. After death, we will not know that we did not live longer anyway. Therefore, instead of using the available life-extending drug rapamycin right away, we may choose to wait for miracle discoveries.

If we believe in immortality, we do not need to be immortal. The essence of any religion is immortality in various forms, and this is what gives the meaning of life to true believers. While only a few can be true religious believers, we can all believe in scientific miracles. For this, we should be familiar with news headlines but not too familiar with the technical details. The devil is in the details. For example, headlines announce:

Jeff Bezos Is Paying For a Way to Make Humans Immortal

How To Reverse Ageing and Stay Young Forever Meet Altos Labs, Silicon Valley’s latest wild bet on living forever

Juan Carlos Izpisua: ‘Within two decades, we will be able to prevent aging’.

The work by Juan Carlos Izpisua Belmonte, an Institute Director at Altos Labs, Inc., is brilliant. It uses genetically modified mice that express the Yamanaka factors [1, 2]. But we cannot genetically modify humans. For that, we would need a time machine to genetically modify our parents or grandparents and then to breed them in the right order to mimic mice that express Yamanaka factors. And then we would need a time machine second time to go to the future to evaluate the effect on others in clinical trials, before modifying our own grandparents.

Regarding ground-breaking studies by Juan Carlos Izpisua Belmonte and co-workers in mice [1, 2]. Although lifespan was not measured in these studies, long-lived genetically engineered mice will probably be created in the near future. Scientific discoveries cannot be predicted, otherwise the discovery has already been made at the moment of prediction. Medical applications can be expected to mainly treat trauma-related conditions [1, 3–5].

I like the science of cellular reprogramming, because it implicitly rejects the dogma that aging is caused by the accumulation of molecular damage, such as DNA damage [6]. This is in line with hyperfunction theory of quasi-programmed aging [7, 8].

Can a combination of small molecules do the same thing as Yamanaka factors? This is possible [9]. But this will be a stroke of extraordinary luck because there is no reason why such molecules should exist, and (if they exist) they have no off-target effects and are not toxic. And we still do not know whether partial reprogramming can extend normal lifespan.

Fortunately, mice have already been genetically modified to live longer by knocking out certain genes upstream and downstream of the IGF-1/mTOR signaling pathway. In these long-lived mice, the activity of the mTOR pathway is decreased [10–15]. It is extraordinarily lucky that a small molecule that inhibits the mTOR pathway exists. And, what is even more extraordinary is that this molecule has been approved for human use since 1999 for organ transplantation. As reviewed in 2007: “one target, mTOR itself, stands out, simply because its inhibitor (rapamycin) is a non-toxic, well-tolerated drug that is suitable for everyday oral administration” [16].
As proposed in 2006: “rapamycin, is already approved for clinical use, available and can be used immediately … rapamycin will be most useful as [an] anti-aging drug to slow down senescence and to prevent diseases” [7].

Starting in 2009, rapamycin was shown to extend lifespan in all species tested, in dozens of strains of mice, at various doses and schedules and was effective when given transiently and started at old age [17–24]. By slowing aging, rapamycin delays age-related diseases and especially cancer [25].

Rapamycin is now taken by an uncountable number of relatively healthy individuals, off-label, to treat aging and, by treating aging, preventing diseases. Rapamycin treatment is rapidly becoming a mainstream anti-aging intervention [26].

But what does all this have to do with Altos Labs? First, potential life-extension with rapamycin may allow us to win time while awaiting future discoveries that will reverse aging. Figuratively, we need to slow time before reversing it; as the title queries, “Does rapamycin slow down time?” [27].

Second, rapamycin alone is unlikely to extend lifespan sufficiently to benefit from Altos Lab’s future discoveries in our lifetime. If Altos Labs would allocate a small percentage of its funding to develop rapamycin-based drug combinations, then additional decades of life extension may be available 3–5 years from now. (The same is applicable to Calico Labs).

There are three overlapping groups of drugs for rapamycin-based combinations:

Group 1: A drug (e.g., metformin, aspirin, angiotensin II receptor blockers, and PDE5 inhibitors) that is useful in several age-related diseases and conditions [28].

Group 2: Drugs that can extend lifespan in mice: Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid [29–31].

Group 3: Gerostatics. In cell culture, gerostatics slow down time (figuratively), decelerating both cellular mass growth, cell cycle progression and conversion to senescence, a process known as geroconversion [32, 33]. (Note: gerostatics should not be confused with senolytics [32]). Rapamycin is a prototypic gerostatic [32, 33]. Gerostatics exert static effects on cell proliferation. In nonproliferating cells, gerostatics decelerate geroconversion. In cell culture, mTOR inhibitors (e.g., rapamycin) may increase cellular reprogramming, potentially by preventing cell senescence [34, 35].

The following gerostatics have been identified in cell culture: nutlin-3a, pan-mTOR inhibitors (such as Torins) and inhibitors of Mek, PI3K and S6K [33].

The number of potential combinations with rapamycin is enormous. All of them cannot be tested in mice. Yet, all of them do not need to be tested. I estimate the number of most important combinations as 200–300, for example, a combination of high doses of rapamycin and low doses of a pan-mTOR inhibitor [36] and/or low doses of mdm-2 and Mek inhibitors and various doses of common drugs such as metformin, acarbose, angiotensin II receptor blockers, aspirin and PDE-5 inhibitors. The full list of potential anti-aging combinations with rapamycin is beyond the scope of this editorial.

**CONFLICTS OF INTEREST**

The author has no conflicts of interest to declare.

**REFERENCES**

1. Wang C, Rabadan Ros R, Martinez-Redondo P, Ma Z, Shi L, Xue Y, et al. In vivo partial reprogramming of myofibers promotes muscle regeneration by remodeling the stem cell niche. Nat Commun. 2021;12(1):3094. https://doi.org/10.1038/s41467-021-23353-z, PMID:34035273

2. Browder KC, REDDY P, Yamamoto M, HAGHANI A, Guillen IG, Sahu S, et al. In vivo partial reprogramming alters age-associated molecular changes during physiological aging in mice. Nature Aging. 2022. https://doi.org/10.1038/s43587-022-00183-2.

3. Lu Y, Brommer B, Tian X, Krishnan A, Meer M, Wang C, et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature. 2020;588(7836):124-9. https://doi.org/10.1038/s41586-020-2975-4, PMID:33268865

4. Cheng F, Wang C, Ji Y, Yang B, Shu J, Shi K, et al. Partial reprogramming strategy for intervertebral disc rejuvenation by activating energy switch. Aging Cell. 2022:e13577. https://doi.org/10.1111/acel.13577, PMID:35266272

5. Chondronasiou D, Gill D, Mosteiro L, Urdinguio RG, Berenguer-Llergo A, Aguilera M, et al. Multi-omic rejuvenation of naturally aged tissues by a single cycle of transient reprogramming. Aging Cell. 2022;21(3):e13578. https://doi.org/10.1111/ace.13578, PMID:35235716

6. Goya RG, Lehmann M, Chiavellini P, Canatelli-Mallat M, HEREñU CB, Brown OA. Rejuvenation by cell reprogramming: a new horizon in gerontology. Stem Cell Research & Therapy. 2018;9(1):349. https://doi.org/10.1186/s13287-018-1075-y, PMID:30558644

7. Blagosklonny MV. Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition. Cell Cycle. 2006;5(18):2087-102. https://doi.org/10.4161/cc.5.18.3288, PMID:17012837

8. Gems D, de la Guardia Y. Alternative Perspectives on Aging in Caenorhabditis elegans: Reactive Oxygen Species or Hyperfunction? Antioxid Redox Signal. 2013;19(3):321-9. https://doi.org/10.1089/ars.2012.4840, PMID:22870907

9. Liu H, Li R, Liao HK, Min Z, Wang C, Yu Y, et al. Chemical combinations potentiate human pluripotent stem
cell-derived 3D pancreatic progenitor clusters toward functional beta cells. Nat Commun. 2021;12(1):3330. https://doi.org/10.1038/s41467-021-23525-x. PMID:34099664

10. Bartke A, Sun LY, Longo V. Somatotropic signaling: trade-offs between growth, reproductive development, and longevity. Physiol Rev. 2013;93(2):571-98. https://doi.org/10.1152/physrev.00006.2012. PMID:23589828

11. Coschigano KT, Clemmons D, Bellush LL, Kopchick JJ. Assessment of growth parameters and life span of GHR/GP gene-disrupted mice. Endocrinology. 2000;141(7):2608-13. https://doi.org/10.1210/endo.141.7.5856. PMID:10875265

12. Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science. 2009;326(5949):140-4. https://doi.org/10.1126/science.1177221. PMID:19797661

13. Wu JJ, Liu J, Chen EB, Wang JJ, Cao L, Narayan N, et al. Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression. Cell Rep. 2013;4(5):913-20. https://doi.org/10.1016/j.celrep.2013.07.030. PMID:23994476

14. Dominick G, Berryman DE, List EO, Kopchick JJ, Li X, Miller RA, et al. Regulation of mTOR activity in Snell dwarf and GH receptor gene-disrupted mice. Endocrinology. 2015;156(2):565-75. https://doi.org/10.1210/en.2014-1690. PMID:25456069

15. Shi X, Endicott SJ, Miller RA. Regulation of mTOR complexes in long-lived growth hormone receptor knockout and Snell dwarf mice. Aging (Albany NY). 2022;14(underscored). https://doi.org/10.18632/aging.203959. PMID:35305083

16. Blagosklonny MV. An anti-aging drug today: from senescence-promoting genes to anti-aging pill. Drug Discov Today. 2007;12(5-6):218-24. https://doi.org/10.1016/j.drudis.2007.01.004. PMID:17331886

17. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-5. https://doi.org/10.1038/nature08221. PMID:19587680

18. Anisimov VN, Zabezhsinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, et al. Rapamycin extends maximal lifespan in cancer-prone mice. Am J Pathol. 2010;176(5):2092-7. https://doi.org/10.2353/ajpath.2010.091050. PMID:20363920

19. Anisimov VN, Zabezhsinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, et al. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle. 2011;10(24):4230-6. https://doi.org/10.4161/cc.22107964

20. Miller RA, Harrison DE, Astle CM, Fernandez E, Flurkey K, Han M, et al. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell. 2014;13(3):468-77. https://doi.org/10.1111/acel.12194. PMID:24341993

21. Zhang Y, Bokov A, Gelfond J, Soto V, Ikeno Y, Hubbard G, et al. Rapamycin extends life and health in C57BL/6 mice. J Gerontol A Biol Sci Med Sci. 2014;69(2):119-30. https://doi.org/10.1093/gerona/glt056. PMID:23682161

22. Johnson SC, Yanos ME, Bitto A, Castanza A, Gagnidze A, Gonzalez B, et al. Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice. Front Genet. 2015;6:247. https://doi.org/10.3389/fgen.2015.00247. PMID:26257774

23. Bitto A, Ito TK, Pineda VV, LeTexier NJ, Huang HZ, Sutlief E, et al. Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice. Elife. 2016;5. https://doi.org/10.7554/eLife.16351. PMID:27549339

24. Arriola Apelo SI, Pumper CP, Baar EL, Cummings NE, Lamming DW. Intermittent Administration of Rapamycin Extends the Life Span of Female C57BL/6J Mice. J Gerontol A Biol Sci Med Sci. 2016;71(7):876-81. https://doi.org/10.1093/gerona/glw064. PMID:27091134

25. Blagosklonny MV. Prevention of cancer by inhibiting aging. Cancer Biol Ther. 2008;7(10):1520-4. https://doi.org/10.4161/cbt.7.10.6663. PMID:18769112

26. Blagosklonny MV. Rapamycin for longevity: opinion article. Aging (Albany NY). 2019;11(19):8048-67. https://doi.org/10.18632/aging.102355. PMID:31586989

27. Blagosklonny MV. Does rapamycin slow down time? Oncotarget. 2018;9(54):30210-2. https://doi.org/10.18632/oncotarget.25788. PMID:30100983

28. Blagosklonny MV. Koschei the immortal and anti-aging drugs. Cell Death Dis. 2014;5:e1552. https://doi.org/10.1038/cddis.2014.520. PMID:25476900

29. Harrison DE, Strong R, Allison DB, Ames BN, Astle CM, Atamna H, et al. Acarbose, 17-alpha-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging Cell. 2014;13(2):273-82. https://doi.org/10.1111/acel.12170. PMID:24245565

30. Strong R, Miller RA, Antebi A, Astle CM, Bogue M, Denzel MS, et al. Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an alpha-glucosidase inhibitor or a Nrf2-inducer. Aging Cell. 2019;18(3):e13323. https://doi.org/10.1111/acel.13323. PMID:30688027

31. Strong R, Miller RA, Antebi A, Astle CM, Bogue M, Denzel MS, et al. Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an alpha-glucosidase inhibitor or a Nrf2-inducer. Aging Cell. 2019;18(3):e13323. https://doi.org/10.1111/acel.13323. PMID:30688027

32. Blagosklonny MV. Anti-aging: senolytics or gerostatics (unconventional view). Oncotarget. 2014;5:e7926. https://doi.org/10.18632/oncotarget.28049. PMID:2540654

33. Blagosklonny MV. Cell senescence, rapamycin and hyperfunction theory of aging. Cell Cycle. 2022 Mar 31:1-12.
34. Menendez JA, Vellon L, Oliveras-Ferraros C, Cufi S, Vazquez-Martin A. mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging. Cell Cycle. 2011;10(21):3658-77. https://doi.org/10.4161/cc.10.21.18128. PMID:22052357

35. Chen T, Shen L, Yu J, Wan H, Guo A, Chen J, et al. Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells. Aging Cell. 2011;10(5):908-11. https://doi.org/10.1111/j.1474-9726.2011.00722.x. PMID:21615676

36. Leontieva OV, Blagosklonny MV. Gerosuppression by pan-mTOR inhibitors. Aging (Albany NY). 2016;8(12):3535-51. https://doi.org/10.18632/aging.101155. PMID:28077803